<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVE: The phosphorylated aminothiol agent <z:chebi fb="0" ids="2636">amifostine</z:chebi> (<z:chebi fb="0" ids="2636">Ethyol</z:chebi>) protects bone marrow and other tissues from toxicity due to ionizing radiation and <z:chebi fb="0" ids="35610">antineoplastic drugs</z:chebi>, and stimulates progenitors from <z:mpath ids='MPATH_458'>normal</z:mpath> and myelodysplastic bone marrow </plain></SENT>
<SENT sid="1" pm="."><plain>Contrasting results have been published so far on the effectiveness of <z:chebi fb="0" ids="2636">amifostine</z:chebi> in correcting cytopenia in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: In a pilot phase II study we treated 26 patients with low risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:chebi fb="0" ids="6067">13 RA</z:chebi>, 2 RARS, 2 CMML, 9 RAEB with blasts &lt; 10%) with <z:chebi fb="0" ids="2636">amifostine</z:chebi> (200 mg/m(2 )x 3/week for 4 weeks) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: <z:chebi fb="0" ids="35143">Hemoglobin</z:chebi> concentration, reticulocyte, neutrophil and <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">platelet counts increased</z:e> respectively in 6 (23%), 11 (42%), 13 (50%) and 9 (34%) of patients </plain></SENT>
<SENT sid="4" pm="."><plain>Red cell transfusions were reduced (&gt; 50%) in 4/26 patients and abolished in 1/26 </plain></SENT>
<SENT sid="5" pm="."><plain>Unexpectedly a significant decrease in soluble transferrin receptor level at week 4 of therapy, compared to the basal level (p&lt;0.04), was observed in the whole population of patients </plain></SENT>
<SENT sid="6" pm="."><plain>INTERPRETATION AND CONCLUSIONS: <z:chebi fb="0" ids="2636">Amifostine</z:chebi> can ameliorate cytopenia in some patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, with few and mild side effects </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0001875'>Neutropenia</z:hpo> is more likely to be corrected than <z:hpo ids='HP_0001903'>anemia</z:hpo> or <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Mechanisms underlying this biological effect remain to be clarified </plain></SENT>
</text></document>